Hazards in perimenopausal contraception

European Journal of Contraception and Reproductive Health Care

Volumn 2, Issue 2, 1997, Pages 95-100

  Schneider, H P G ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

Bone metabolism; Cancer risk; Cardiovascular risk; Perimenopausal contraception

Indexed keywords

ORAL CONTRACEPTIVE AGENT;

AGE; CARDIOVASCULAR DISEASE; CHEMICALLY INDUCED DISORDER; FEMALE; FERTILITY; HUMAN; MENOPAUSE; MIDDLE AGED; NEOPLASM; PHYSIOLOGY; PREMENOPAUSE; REVIEW; RISK FACTOR;

AGE FACTORS; CARDIOVASCULAR DISEASES; CONTRACEPTIVES, ORAL; FEMALE; FERTILITY; HUMANS; MENOPAUSE; MIDDLE AGED; NEOPLASMS; PREMENOPAUSE; RISK FACTORS;

EID: 0031151216     PISSN: 13625187     EISSN: None     Source Type: Journal    
DOI: 10.3109/13625189709167461     Document Type: Article

References (19)

1. Brambilla DJ, McKinlay SM, Johannes CB. Defining the perimenopause for application in epidemiologic investigations. Am J Epidemiol 1994; 140: 1091-5
2. Croft P, Hannaford PC. Risk factors for acute myocardial infarction in women: evidence from the RCGP oral contraception study. Br Med J 1989; 298: 165-8
3. Metcalf MG. Incidence of ovulatory cycles in women approaching menopause. J Biosoc Sci 1979; 11: 39-48
4. Kirkman RJE. From contraception to menopause. In Crosignani PG, Paoletti R, Sarrel PM, Wenger NK, eds. Women's Health in Menopause. London: Kluwer Academic Publishers, 1994: 207-12
5. Oral contraception in the perimenopause. Drug Ther Bull 1991; 29: 3-4
6. Kirkman RJE. Contraceptive options for the 'older' woman. Eur Menopause J 1995; 2: 10-12
7. Schneider HPG, Hauser GA. The Menopause Rating Scale (MRS II) - clusters of menopausal symptoms. Presented at the 8th International Congress on the Menopause, Sydney, 1997; abstract
8. Drife JO. The benefits of combined oral contraceptives. Br J Obstet Gynaecol 1989; 96: 1225-8
9. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer in hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Lancet 1996; 347: 1713-27
10. The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development. Combination oral contraceptive use and the risk of endometrial cancer. J Am Med Assoc 1987; 257: 796
11. The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development.The reduction in risk of ovarian cancer associated with oral contraceptive use. N Engl J Med 1987; 316: 650
12. Rosenberg L, Shapiro S, Slone D et al. Epithelial ovarian cancer and combination oral contraceptives. J Am Med Assoc 1982; 247: 3210
13. Willet PC, Bain C, Hennekens CH et al. Oral contraceptives and the risk of ovarian cancer. Cancer 1981; 48: 1684
14. Inman WHB, Vessey MP, Westerholm B et al. Thromboembolic disease and the steroidal content of oral contraceptives: a report to the Committee on Safety of Drugs. Br Med J 1970; 2: 203
15. Bauersachs R, Lindhoff-Last E, Ehrly AM, Kuhl H. The significance of hereditary thrombophilia for the risk of thrombosis associated with oral contraception. Zbl Gynäkol 1996; 118: 262-70
16. Rosenberg L, Kaufman DW, Helmrich SP et al. Myocardial infarction and cigarette smoking in women younger than 50 years of age. J Am Med Assoc 1985; 253: 2965
17. Stampfer MJ, Willett WC, Colditz GA et al. A prospective study of past use of oral contraceptive agents and risk of cardiovascular diseases. N Engl J Med 1988; 319; 1313
18. Lewis MA, Spitzer WO, Heinemann LAJ et al. Third-generation oral contraceptives and risk of myocardial infarction: an international case-control study. Br Med J 1996; 312: 88-90
19. Gambacciani M, Spinetti A, Cappagli B et al. Hormone replacement therapy in perimenopausal women with a low-dose oral contraceptive preparation: effects on bone mineral density and metabolism. Maturitas 1994; 19: 125-31